相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diagnosis and Management of Multiple Myeloma A Review
Andrew J. Cowan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Junctional adhesion molecule C expression specifies a CD138low/neg multiple myeloma cell population in mice and humans
Andreas Brandl et al.
BLOOD ADVANCES (2022)
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression
Antonio G. Solimando et al.
HAEMATOLOGICA (2021)
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma
Stephan R. Bohl et al.
BLOOD ADVANCES (2021)
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
Madelon M. E. de Jong et al.
NATURE IMMUNOLOGY (2021)
MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease
Vanessa Desantis et al.
CANCERS (2021)
The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer
Domenico Ribatti et al.
CANCERS (2021)
RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS
Marcel Seibold et al.
HAEMATOLOGICA (2020)
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement
Matteo Claudio Da Via et al.
ONCOLOGIST (2020)
CRISPR-engineered T cells in patients with refractory cancer
Edward A. Stadtmauer et al.
SCIENCE (2020)
Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
Giuseppe Di Lernia et al.
JOURNAL OF CLINICAL MEDICINE (2020)
HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma
Luigia Rao et al.
CANCERS (2020)
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Pinto et al.
CANCERS (2020)
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Ilaria Saltarella et al.
CELLS (2020)
Immune system and bone microenvironment: rationale for targeted cancer therapies
Gnoni Antonio et al.
Oncotarget (2020)
MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance
Vanessa Desantis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Timing the initiation of multiple myeloma
Even H. Rustad et al.
NATURE COMMUNICATIONS (2020)
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
Antonella Argentiero et al.
JOURNAL OF CLINICAL MEDICINE (2020)
A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche
Antonio Giovanni Solimando et al.
JOURNAL OF ONCOLOGY (2020)
New Insights into Diffuse Large B-Cell Lymphoma Pathobiology
Antonio Giovanni Solimando et al.
CANCERS (2020)
Actors on the Scene: Immune Cells in the Myeloma Niche
Patrizia Leone et al.
FRONTIERS IN ONCOLOGY (2020)
The dormant cancer cell life cycle
Tri Giang Phan et al.
NATURE REVIEWS CANCER (2020)
Bone marrow niches in haematological malignancies
Simon Mendez-Ferrer et al.
NATURE REVIEWS CANCER (2020)
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Oksana Zavidij et al.
NATURE CANCER (2020)
Myeloma bone disease: from biology findings to treatment approaches
Evangelos Terpos et al.
BLOOD (2019)
The relationship between autophagy and the immune system and its applications for tumor immunotherapy
Guan-Min Jiang et al.
MOLECULAR CANCER (2019)
A niche-dependent myeloid transcriptome signature defines dormant myeloma cells
Weng Hua Khoo et al.
BLOOD (2019)
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Benjamin G. Barwick et al.
FRONTIERS IN IMMUNOLOGY (2019)
High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment
Antonio Giovanni Solimando et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma Research
Sophia Loda et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
Antonella Argentiero et al.
CANCERS (2019)
Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival
Antonio Giovanni Solimando et al.
BLOOD (2019)
Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes
Maria Antonia Frassanito et al.
JOURNAL OF PATHOLOGY (2019)
Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients
Patrizia Leone et al.
ONCOIMMUNOLOGY (2019)
Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
Danielle Harmer et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
JAM-A as a prognostic factor and new therapeutic target in multiple myeloma
A. G. Solimando et al.
LEUKEMIA (2018)
Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma
Vanessa Desantis et al.
ANNALS OF HEMATOLOGY (2018)
Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial
Angelo Vacca et al.
CLINICAL IMMUNOLOGY (2018)
Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
Ingrid Spaan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
The multiple myelomas - current concepts in cytogenetic classification and therapy
Shaji K. Kumar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Mouse models of multiple myeloma: technologic platforms and perspectives
Marco Rossi et al.
Oncotarget (2018)
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
Aurelia Lamanuzzi et al.
Oncotarget (2018)
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study
Luigia Rao et al.
Oncotarget (2018)
A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis A case report
Antonio G. Solimando et al.
MEDICINE (2018)
Genomic patterns of progression in smoldering multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2018)
Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease
Antonio Giovanni Solimando et al.
BLOOD (2018)
Suspected Pericardial Tuberculosis Revealed as an Amyloid Pericardial Mass
Sebastiano Cicco et al.
CASE REPORTS IN HEMATOLOGY (2018)
Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth
Renate Burger et al.
HAEMATOLOGICA (2017)
Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth
Renate Burger et al.
HAEMATOLOGICA (2017)
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
The small subunit of Hemilipin2, a new heterodimeric phospholipase A2 from Hemiscorpius lepturus scorpion venom, mediates the antiangiogenic effect of the whole protein
Imen Jridi et al.
TOXICON (2017)
Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development
Federica Papaccio et al.
STEM CELLS TRANSLATIONAL MEDICINE (2017)
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Tea Gogishvili et al.
BLOOD (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau et al.
BLOOD (2017)
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Hans Erik Johnsen et al.
HAEMATOLOGICA (2016)
The immune system and cancer evasion strategies: therapeutic concepts
S. Muenst et al.
JOURNAL OF INTERNAL MEDICINE (2016)
Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
Jinheng Wang et al.
JOURNAL OF PATHOLOGY (2016)
Targeting vasculogenesis to prevent progression in multiple myeloma
M. Moschetta et al.
LEUKEMIA (2016)
Targeting B-cell non Hodgkin lymphoma: New and old tricks
Antonio Giovanni Solimandoa et al.
LEUKEMIA RESEARCH (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems
Shaunna L. Beedie et al.
ONCOTARGET (2016)
Microenvironment drug resistance in multiple myeloma: emerging new players
Lucia Di Marzo et al.
ONCOTARGET (2016)
Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
Jinheng Wang et al.
ONCOTARGET (2016)
The myeloma stem cell concept, revisited: from phenomenology to operational terms
Hans Erik Johnsen et al.
HAEMATOLOGICA (2016)
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing
Patrizia Leone et al.
BLOOD (2015)
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy
Rama K. Mishra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Naoko Takebe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Targeting the WNT Signaling Pathway in Cancer Therapeutics
David Tai et al.
ONCOLOGIST (2015)
Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche
Michelle A. Lawson et al.
NATURE COMMUNICATIONS (2015)
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
Alessandro Canella et al.
ONCOTARGET (2015)
Identify multiple myeloma stem cells: Utopia?
Ilaria Saltarella et al.
WORLD JOURNAL OF STEM CELLS (2015)
Targeting the bone marrow microenvironment in multiple myeloma
Yawara Kawano et al.
IMMUNOLOGICAL REVIEWS (2015)
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome
Annamaria Brioli et al.
BLOOD (2014)
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Jens G. Lohr et al.
CANCER CELL (2014)
A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target
Arianna Ferrucci et al.
CLINICAL CANCER RESEARCH (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications
C. C. Bjorklund et al.
LEUKEMIA (2014)
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
L. Melchor et al.
LEUKEMIA (2014)
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolo Bolli et al.
NATURE COMMUNICATIONS (2014)
High-Throughput Flow Cytometry Screening Reveals a Role for Junctional Adhesion Molecule A as a Cancer Stem Cell Maintenance Factor
Justin D. Lathia et al.
CELL REPORTS (2014)
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Michele Moschetta et al.
CLINICAL CANCER RESEARCH (2013)
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials
Sara Bringhen et al.
HAEMATOLOGICA (2013)
Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature
Judith Payet et al.
LEUKEMIA & LYMPHOMA (2013)
WNT signalling pathways as therapeutic targets in cancer
Jamie N. Anastas et al.
NATURE REVIEWS CANCER (2013)
Germinal Centers
Gabriel D. Victora et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Paola Neri et al.
CURRENT CANCER DRUG TARGETS (2012)
Integrin-linked kinase is dispensable for multiple myeloma cell survival
Torsten Steinbrunn et al.
LEUKEMIA RESEARCH (2012)
Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?
J. E. Noll et al.
BLOOD CANCER JOURNAL (2012)
Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
Roberto Ria et al.
STEM CELLS INTERNATIONAL (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival
Torsten Steinbrunn et al.
BLOOD (2011)
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Dirk Hose et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J. Morgan et al.
LANCET ONCOLOGY (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
Angiogenesis and Multiple Myeloma
Nicola Giuliani et al.
CANCER MICROENVIRONMENT (2011)
The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients
Yanran Cao et al.
EXPERIMENTAL HEMATOLOGY (2010)
Role of Wnt canonical pathway in hematological malignancies
G. E. Xueling et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Infections in Patients with Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents
Marcio Nucci et al.
CLINICAL INFECTIOUS DISEASES (2009)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
Wee J. Chng et al.
CANCER RESEARCH (2007)
Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo
R. Schmidmaier et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2006)
Crosstalk between cancer cells and bone microenvironment in bone metastasis
T Yoneda et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis
K Mahtouk et al.
BLOOD (2004)
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
Y Nefedova et al.
BLOOD (2004)
Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis
JD Hood et al.
JOURNAL OF CELL BIOLOGY (2003)
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms
Y Nefedova et al.
LEUKEMIA (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway
M Chatterjee et al.
BLOOD (2002)
Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation
SA Ely et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Chromosome translocations in multiple myeloma
PL Bergsagel et al.
ONCOGENE (2001)
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia
HG Drexler et al.
LEUKEMIA RESEARCH (2000)
Role of interleukin-6 in the pathogenesis of multiple myeloma
K Gado et al.
CELL BIOLOGY INTERNATIONAL (2000)
分享论文
